Exploiting this vulnerability pharmacologically, we show that mesothelioma cells lacking BAP1 are more susceptible to the mevalonate pathway inhibitor zoledronic acid (ZA), identifying another Bap1-loss-specific vulnerability. The gene discussed is BAP1; the disease is mesothelioma.